Anales RANF

Nannocannabinoids for brain tumor drug delivery @Real Academia Nacional de Farmacia. Spain 209 Figure 7: Example of 3D reconstruction from the Z-stacks of the images taken by confocal microscopy for DiO- labeled LNCs within U373MG cells. 3.3. Determination of the in vitro efficacy of CBD-loaded LNCs as extended-release carriers against U373MG cells Monodisperse LNCs with the Labrafac ® -Kolliphor ® HS15 tandem loaded with CBD at a concentration of 15 % CBD/ Labrafac ® WL1349 (w/w) were prepared in two different sizes for in vitro efficacy experiments under the assumption that LNCs contribute to overcome classical formulation problems associated with cannabinoids (61) and to attain a prolonged-release platform for this drug. The liquid lipid core of triglyceride oils was chosen on the grounds of the solubility of CBD to achieve both high encapsulation efficiencies and drug loading (Table S1). Concerning particle size, the encapsulation of CBD followed the inverse pattern than its adsorption: the percentage increase in particle size in comparison to their blank counterparts was more evident for the bigger LNCs (Figure 8). These results positively correlated with the percentage of CBD loading, which ranged from 4.30% for the smaller LNCs to 7.66% for the bigger ones (Table S1). Moreover, in agreement with the hypothesized encapsulation, the zeta potential profiles were not changed in comparison to those obtained for blank LNCs (Figure S1): values close to neutrality with high profile width were obtained in all cases. Figure 8: Average volume diameter of the different LNCs used to assess the in vitro efficacy against glioma: blank LNCs (orange) and CBD-loaded LNCs (pistachio). The smaller-sized formulation of each type has a squared fill pattern, whereas the bigger-sized has a striped fill pattern.